Bristol Myers' Opdivo-Yervoy Combo Approved In Europe, Canada For Malignant Pleural Mesothelioma

The regulatory authorities in Europe and Canada have approved Bristol Myers Squibb & Co's BMY Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adults with unresectable malignant pleural mesothelioma (MPM).
The approvals are based on results from the CheckMate -743 trial.
The trial met its primary endpoint, showing superior overall survival (OS) of 18.1 months with Opdivo plus Yervoy versus 14.1 months for chemotherapy (pemetrexed and cisplatin or carboplatin).
Mesothelioma is a rare and aggressive form of cancer mainly caused by asbestos exposure. It most often affects the pleural lining (the lining surrounding the lungs).
Price Action: BMY shares are up 0.38% at $65.35 during the market session on the last check Wednesday.

Momentum47.49

Growth70.71

QualityNot Available

Value29.89

Short

Medium

Long